Molecular genetics of Marfan syndrome

Current Opinion in Cardiology

Volumn 20, Issue 3, 2005, Pages 194-200

  Boileau, Catherine ^a,b,f   Jondeau, Guillaume ^b   Mizuguchi, Takeshi ^c,d,e   Matsumoto, Naomichi ^d,e  

^a INSERM   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Fibrillin 1; Genetics; Marfan; Transforming growth factor ; Transforming growth factor receptors

Indexed keywords

FIBRILLIN 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ANEURYSM; CHROMOSOME 15Q; CHROMOSOME 3P; CONNECTIVE TISSUE DISEASE; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MARFAN SYNDROME; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MARFAN SYNDROME; MICROFIBRILS; MICROFILAMENT PROTEINS; MOLECULAR BIOLOGY; MUTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 18944392585     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000162398.21972.cd     Document Type: Review

References (56)

1. Pyeritz RE. The Marfan syndrome. Annu Rev Med 2000; 51:481-510.
2. Lee B, Godfrey M, Vitale E, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature 1991; 352:330-334.
3. Dietz H, Cutting G, Pyeritz R, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352:337-339.
4. Beighton P, De-Paepe D, Danks D. International nosology of heritable disorders of connective tissue. Am J Med Genet 1988; 29:581-594.
5. Kainulainen K, Pulkkinen L, Savolainen A, et al. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med 1990; 323:935-939.
6. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62:417-426.
7. Boileau C, Jondeau G, Babron MC, et al. Familial Marfan-like aortic dilatation and skeletal anomalies are not linked to the fibrillin genes. Am J Hum Genet 1993; 53:46-54.
8. Collod G, Babron MC, Jondeau G, et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet 1994; 8:264-268.
9. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004; 36:855-860. This study clearly shows genetic heterogeneity of Marian syndrome and also a - direct link between a connective tissue disorder and TGF-β signaling in humans. In-vitro functional studies implied that the nature of missense mutations is loss of function.
10. Corson GM, Chalberg SC, Dietz HC, et al. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5′ end. Genomics 1993; 2:476-484.
11. Collod-Beroud G, Le Bourdelles S, Ades L, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003; 22:199-208.
12. Loeys B, De Backer J, Van Acker P, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 2004; 24:140-146. Interesting discussion on gene screening strategies and the detection rate of FBN1 mutations.
13. Tiecke F, Katzke S, Booms P, et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype - phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet 2001; 9:13-21.
14. Palz M, Tiecke F, Booms P, et al. Clustering of mutations associated with mild Marfan-like phenotypes in the 3′ region of FBN1 suggests a potential genotype-phenotype correlation. Am J Med Genet 2000; 91:212-221.
15. Dietz HC, Mclntosh I, Sakai LY, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF'like domain calcium binding in the pathogenesis of Marfan syndrome, Genomics 1993; 17:468-475.
16. Nijbroek G, Sood S, McIntosh I, et al. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 1995; 57:8-21.
17. Karttunen L, Ukkonen T, Kainulainen K, et al. Two novel fibrillin-1 mutations resulting in premature termination codons but in different mutant transcript levels and clinical phenotypes. Hum Mutat 1998; (Suppl 1):S34-S37.
18. Schrijver I, Liu W, Odom R, et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet 2002; 71:223-237.
19. Whiteman P, Handford PA. Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders. Hum Mol Genet 2003; 12:727-737.
20. Schrijver I, Liu W, Brenn T, et al. Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet 1999; 65:1007-1020.
21. Booms P, Tiecke F, Rosenberg T, et al. Differential effect of FBN1 mutations on in vitro proteolysis of recombinant fibrillin-1 fragments. Hum Genet 2000; 107:216-224.
22. Vollbrandt T, Tiedemann K, El-Hallous E, et al. Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1. J Biol Chem 2004; 279:32924-32931. Further in-vitro data to support the existence of enhanced susceptibility of mutated fibrillin-1 to metalloproteases.
23. Adès LC, Holman KJ, Brett MS, et al. Ectopia lentis phenotypes and the FBN1 gene. Am J Med Genet 2004; 126A;284-289. This paper is the first to gather all the molecular and clinical data obtained for ectopia lentis either as an isolated trait or associated with various degrees of skeletal, integumentary involvement, mitral valve prolapse, and mild nonprogressive aortic dilatation.
24. Reinhardt DP, Ono RN, Notbohm H, et al. Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis: a potential disease-causing mechanism in Marfan syndrome. J Biol Chem 2000; 275:1239-1245.
25. Downing AK, Knott V, Werner JM, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. Cell 1996; 85:597-605.
26. Judge DP, Biery NJ, Keene DR, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004; 114:172-181.
27. Revencu N, Quenum G, Detaille T, et al. Congenital diaphragmatic eventration and bilateral uretero-hydronephrosis in a patient with neonatal Marfan syndrome caused by a mutation in exon 25 of the FBN1 gene and review of the literature. Eur J Pediatr 2004; 163:33-37. Most recent and rare review on molecular genetics of neonatal Marfan syndrome as well as a complete clinical description of the form. Excellent reference for clinicians unfamiliar with this severe and sporadic form.
28. Smallridge RS, Whiteman P, Werner JM, et al. Solution structure and dynamics of a calcium binding epidermal growth factor-like domain pair from the neonatal region of human fibrillin-1. J Biol Chem 2003; 278:12199-12206.
29. Adès LC, Haan EA, Colley AF, et al. Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome. J Med Genet 1996; 33:665-671.
30. Loeys B, Nuytinck L, Delvaux I, et al. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 2001; 161: 2447-2454.
31. Buoni S, Zannoli R, Maccuci F, et al. The FBN1 (R2726W) mutation is not fully penetrant. Ann Hum Genet 2004; 68:633-638.
32. Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997; 17:218-222.
33. Pereira L, Lee SY, Gayraud B, et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA 1999; 96:3819-3823.
34. Hutchinson S, Furger A, Halliday D, et al. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum Mol Genet 2003; 18:2269-2276.
35. Giusti B, Porciani MC, Brunelli T, et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome: possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J 2003; 24: 2038-2045.
36. Katzke S, Booms P, Tiecke F, et al. TGGE screening of the entire FBN1 coding sequence in 126 individuals with Marfan syndrome and related fibrillinopathies. Hum Mutat 2002; 20:197-208.
37. Biggin A, Holman K, Brett M, et al. Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat - mutation in Brief # 678 2004 This paper describes a highly efficient strategy to screen the FBN1 gene for mutations in Marfan probands.
38. Milewicz D, Grossfield J, Cao SN, et al. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 1995; 95:2373-2378.
39. Milewicz D, Fisher KM, Coselli J, et al. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 1996; 94:2708-2711.
40. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37:275-281. Authors presented a new aortic aneurysm syndrome caused by either TGFBR1 or TGFBR2 mutations. In this syndrome, histologic findings of aortic walls are similar to those in classic Marfan syndrome and increased TGF-β signaling activity was recognized immunohistochemically.
41. Greally MT, Carey JC, Milewicz DM, et al. Shprintzen-Goldberg syndrome: a clinical analysis. Am J Med Genet 1998; 76:202-212.
42. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003; 278:2750-2757.
43. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33:407-411.
44. Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004; 114:1586-1592.
45. Kaartinen V, Warburton D. Fibrillin controls TGF-beta activation. Nat Genet 2003; 33:331-332.
46. Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in TGFβ1 result in Camurati-Engelmann disease. Nat Genet 2000; 26:19-20.
47. Serra R, Karaplis A, Sohn P. Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J Cell Biol 1999; 145:783-794.
48. Alvarez J, Serra R. Unique and redundant roles of Smad3 in TGF-beta-mediated regulation of long bone development in organ culture. Dev Dyn 2004; 230:685-699.
49. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999; 59:320-324.
50. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261:4337-4345.
51. Sinha S, Heagerty AM, Shuttleworth CA, et al. Expression of latent TGF-beta binding proteins and association with TGF-beta 1 and fibrillin-1 following arterial injury. Cardiovasc Res 2002; 53:971-983.
52. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116:217-224,
53. Nakamura T, Lozano PR, Ikeda Y, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002; 415:171-175.
54. Yanagisawa H, Davis EC, Starcher BC, et al. Fibulin-5 is an elastin-binding protein essential for elastic fiber development in vivo. Nature 2002; 415:168-171.
55. Azhar M, Schultz Jel J, Grupp I, et al. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 2003; 14:391-407.
56. Kaartinen V, Voncken JW, Shuler C, et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995; 11:415-421.